MULTİPL SKLEROZUN EKONOMİK YÜKÜ

Selin Kalender

MULTİPL SKLEROZUN EKONOMİK YÜKÜ

Abstract

Multipl Skleroz (MS), en yaygın nörolojik sağlık sorunlarından biridir. Sıklıkla genç yetişkinlik döneminde görülmektedir. Hastalık, uzun süre hayatta kalma ve zaman içinde artan engellilik durumu ile karakterizedir. Tedavi maliyetlerinin yüksek olması ve hastaların uzun süre bakıma ihtiyaç duymaları nedeniyle MS, sağlık hizmetleri için ayrılan kaynaklara olan talebin hızla yükseldiği bir sağlık problemi haline gelmiştir. Hastalığın toplam maliyetleri hastalar, aileler ve toplum üzerinde ağır bir yük oluşturmaktadır. Özellikle hastalarda oluşturduğu engellilik nedeniyle hastalığın ilerleyen evrelerinde toplam maliyetlerinin daha da yükseldiği belirtilmektedir. Bu çalışmada; literatürde MS’in ekonomik yükünün ortaya konulması amacı ile yapılan çalışmaların sonuçlarından yola çıkılarak hastalığın sağlık hizmetleri sistemi ve toplum üzerinde oluşturduğu ekonomik yük hakkında bilgi verilmesi amaçlanmıştır. Yapılan çalışmalarda MS’in ilaç tedavileri, informal bakım maliyetleri ve verimlilik kayıpları başta olmak üzere toplam maliyetlerinin hızla yükseldiği bir sağlık problemi olduğu belirtilmektedir. Bu bakımdan hastalık ile ilgili önlemlerin acilen alınması gerektiği ifade edilmektedir. Bu çalışma, MS’in yükselen maliyetleri nedeniyle oluşturduğu ekonomik yük hakkında karar vericiler başta olmak üzere hastalık ile tüm paydaşlarda farkındalık oluşturması açısından önemli bilgiler içermektedir. Bununla birlikte hastalığın ekonomik yüküne dair daha kapsamlı sonuçların sunulabilmesi için sistematik derleme ve meta analiz gibi kanıt değeri yüksek çalışmalarının yapılmasına ihtiyaç olduğu düşünülmektedir.

Keywords

References

Adelman, G., Rane, S. G. ve Villa, K. F. (2013). The Cost Burden of Multiple Sclerosis in the United States: A Systematic Review of the Literature. Journal of Medical Economics, 16(5), 639–647. https://doi.org/10.3111/13696998.2013.778268
Amato, M. P., Battaglia, M. A., Caputo, D., Fattore, G., Gerzeli, S., Pitaro, M., Reggio, A., Trojano, M. ve Mu.S.I.C Study Group. (2002). The costs of multiple sclerosis: A cross-sectional, multicenter cost-of-illness study in Italy. Journal of Neurology, 249(2), 152–163. https://doi.org/10.1007/PL00007858
Battaglia, M., Kobelt, G., Ponzio, M., Berg, J., Capsa, D. and Dalén, J. (2017). New Insights into the Burden ve Costs of Multiple Sclerosis in Europe: Results for Italy. Multiple Sclerosis Journal, 23(2_suppl), 104–116. https://doi.org/10.1177/1352458517708176
Berg, J., Lindgren, P., Fredrikson, S. ve Kobelt, G. (2006). Costs and quality of life of multiple sclerosis in Sweden. European Journal of Health Economics, 7(2_suppl.), S75-85. https://doi.org/10.1007/s10198-006-0379-5
Berger, M. L., Kobelt, G., Berg, J., Capsa, D. ve Gannedahl, M. (2017). New Insights into the Burden and Costs of Multiple Sclerosis in Europe: Results for Austria. Multiple Sclerosis Journal, 23(2_suppl), 17–28. https://doi.org/10.1177/1352458517708099
Blahova-Dusankova, J., Kalincik, T., Dolezal, T., Kobelt, G. ve Havrdova, E. (2012). Cost of multiple sclerosis in the Czech Republic: The COMS study. Multiple Sclerosis Journal, 18(5), 662–668. https://doi.org/10.1177/1352458511424422
Boyko, A., Kobelt, G., Berg, J., Boyko, O., Popova, E., Capsa, D. ve Eriksson, J. (2017). New Insights into the Burden and Costs of Multiple Sclerosis in Europe: Results for Russia. Multiple Sclerosis Journal, 23(2_suppl), 155–165. https://doi.org/10.1177/1352458517708668
Brundin, L., Kobelt, G., Berg, J., Capsa, D. ve Eriksson, J. (2017). New Insights into the Burden and Costs of Multiple Sclerosis in Europe: Results for Sweden. Multiple Sclerosis Journal, 23(2_suppl), 179–191. https://doi.org/10.1177/1352458517708682

Calabrese, P., Kobelt, G., Berg, J., Capsa, D. ve Eriksson, J. (2017). New Insights into the Burden and Costs of Multiple Sclerosis in Europe: Results for Switzerland. Multiple Sclerosis Journal, 23(2_suppl), 192–203. https://doi.org/10.1177/1352458517708685
Cerqueira, J. J., Compston, A., Geraldes, R., Rosa, M. M., Schmierer, K., Thompson, A. J., Tinelli, M. ve Palace, J. (2018). Time Matters in Multiple Sclerosis: Can Early Treatment and Long-Term follow-up Ensure Everyone Benefits from the Latest Advances in Multiple Sclerosis? Journal of Neurology, Neurosurgery and Psychiatry, 89(8), 844–850. https://doi.org/10.1136/jnnp-2017-317509
Ernstsson, O., Gyllensten, H., Alexanderson, K., Tinghög, P., Friberg, E. ve Norlund, A. (2016). Cost of Illness of Multiple Sclerosis - A Systematic Review. PLOS ONE, 11(7), 1–25. https://doi.org/10.1371/journal.pone.0159129
Flachenecker, P., Kobelt, G., Berg, J., Capsa, D. ve Gannedahl, M. (2017). New Insights into the Burden and Costs of Multiple Sclerosis in Europe: Results for Germany. Multiple Sclerosis Journal, 23(2_suppl), 78–90. https://doi.org/10.1177/1352458517708141
Fogarty, E., Walsh, C., McGuigan, C., Tubridy, N. ve Barry, M. (2014). Direct and Indirect Economic Consequences of Multiple Sclerosis in Ireland. Applied Health Economics and Health Policy, 12(6), 635–645. https://doi.org/10.1007/s40258-014-0128-3
Gold, R., Toumi, M., Meesen, B. ve Fogarty, E. (2016). The Payer’s Perspective: What is the Burden of MS and How Should the Patient’s Perspective be Integrated in Health Technology Assessment Conducted for Taking Decisions on Access to Care and Treatment? Multiple Sclerosis, 22(2S), 60–70. https://doi.org/10.1177/1352458516650743
Henriksson, F., Fredrikson, S., Masterman, T. ve Jönsson, B. (2001). Costs, Quality of Life and Disease Severity in Multiple Sclerosis: A Cross-Sectional Study in Sweden. European Journal of Neurology, 8(1), 27–35. https://doi.org/10.1046/j.1468-1331.2001.00169.x
Karabudak, R., Karampampa, K. ve Çalışkan, Z. (2015). Treatment Experience, Burden, and Unmet Needs (TRIBUNE) in MS Study: Results from Turkey. Journal of Medical Economics,18(1), 69-75. https://doi.org/10.3111/13696998.2014.950420
Karampampa, K., Gustavsson, A., Miltenburger, C., Kindundu, C. M. ve Selchen, D. H. (2012a). Treatment Experience, Burden, and Unmet Needs (TRIBUNE) in Multiple Sclerosis: The Costs and Utilities of MS patients in Canada. Journal of Population Therapeutics and Cinical Pharmacology, 19(1), e11-25.
Karampampa, K., Gustavsson, A., Miltenburger, C. ve Eckert, B. (2012b). Treatment Experience, Burden and Unmet Needs (TRIBUNE) in MS Study: Results from Five European Countries. Multiple Sclerosis Journal, 18(2_suppl), 7–15. https://doi.org/10.1177/1352458512441566
Kobelt, G. (2010). Sağlık Ekonomisi: Ekonomik Değerlendirmeye Giriş İkinci Baskının Çevirisi (2. Baskı). (Ç, Değer. Çev.), Londra Office Health Economics: Irisal (Orijinal Eserin Basım Tarihi 2002).
Kobelt, G., Berg, J., Atherley, D., Hadjimichael, O. ve Jönsson, B. (2004). Costs and Quality of Life in Multiple Sclerosis-A Cross-Sectional Study in the USA (Working Paper No. 594). SSE/EFI Working Paper Series in Economics and Finance.
Kobelt, G., Berg, J., Lindgren, P., Anten, B., Ekman, M., Longen, P. J. H., Polman, C. ve Uitdehaag, B. (2006a). Costs and quality of life in multiple sclerosis in The Netherlands. European Journal of Health Economics, 7(2), 55–64. https://doi.org/10.1007/s10198-006-0378-6
Kobelt, G., Berg, J., Lindgren, P., Baumhackl, U., Berger, T., Kolleger, H. ve Vass, K. (2006b). Costs and quality of life of multiple sclerosis in Austria. European Journal of Health Economics, 7(2_suppl.), S14–S23. https://doi.org/10.1007/s10198-006-0382-x
Kobelt, G., Berg, J., Lindgren, P., Izquierdo, G., Sánchez-Soliño, O., Pérez-Miranda, J. ve Casado, M. A. (2006c). Costs and Quality of Life of Multiple Sclerosis in Spain. The European Journal of Health Economics, 7(2), S65–S74. https://doi.org/10.1007/s10198-006-0381-y
Kobelt, G., Berg, J., Lindgren, P., Gerfin, A. ve Lutz, J. (2006d). Costs and Quality of Life of Multiple Sclerosis in Switzerland. European Journal of Health Economics, 7(2_suppl.), S86-95. https://doi.org/10.1007/s10198-006-0383-9
Kobelt, G., Texier-Richard, B. ve Lindgren, P. (2009). The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions. Multiple Sclerosis, 15(6), 741–751. https://doi.org/10.1177/1352458509102771
Kobelt, G., Thompson, A. J., Berg, J., Gannedahl, M. ve Eriksson, J. (2017a). New Insights into the Burden and Costs of Multiple Sclerosis in Europe. Multiple Sclerosis Journal, 23(8), 1123–1136. https://doi.org/10.1177/1352458517694432
Kobelt, G., Eriksson, J., Phillips, G. ve Berg, J. (2017b). The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms. Multiple Sclerosis Journal, 23(2_suppl), 4–16. https://doi.org/10.1177/1352458517708097
Kürtüncü, M. ve Eraksoy, M. (2008). Multipl Skleroz: Epigenetik Bir Hastalık Olabilir mi? Nöropsikiyatri Arşivi, 45(Özel Sayı), 15–20. Kurtzke, J. F. (1983). Rating Neurologic Impairment in Multiple Sclerosis: An Expanded Disability Status Scale (EDSS). Neurology, 33(11), 1444–1452. https://doi.org/10.1212/wnl.33.11.1444
Lebrun-Frenay, C., Kobelt, G., Berg, J., Capsa, D. ve Gannedahl, M. (2017). New insights into the burden and costs of multiple sclerosis in Europe: Results for France. Multiple Sclerosis Journal, 23(2_suppl), 65–77. https://doi.org/10.1177/1352458517708125
Lublin, F. D. ve Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology, 46(4), 907–911. https://doi.org/10.1212/WNL.46.4.907
Mirza, M. (2002). Multipl Sklerozun Etyoloji ve Epidemiyolojisi. Erciyes Medical Journal, 24(1), 40–47.
Naci, H., Fleurence, R., Birt, J. ve Duhig, A. (2010). Economic Burden of Multiple Sclerosis: A Systematic Review of the Literature. PharmacoEconomics, 28(5), 363–379. https://doi.org/10.2165/11532230-000000000-00000
Noyes, K., Bajorska, A., Chappel, A., Schwid, S. R., Mehta, L. R., Weinstock-Guttman, B., Holloway, R. G. ve Dick, A. W. (2011). Cost-Effectiveness of Disease-Modifying Therapy for Multiple Sclerosis: A Population-Based Study. Neurology, 77(4), 355–363. https://doi.org/10.1212/WNL.0b013e3182270402
Oreja-Guevara, C., Kobelt, G., Berg, J., Capsa, D. ve Eriksson, J. (2017). New Insights into the Burden and Costs of Multiple Sclerosis in Europe: Results for Spain. Multiple Sclerosis Journal, 23(2_suppl), 166–178. https://doi.org/10.1177/1352458517708672
Orlewska, E., Mierzejewski, P., Zaborski, J., Kruszewska, J., Wicha, W., Fryze, W., Drozdowski, W., Skibicka, I., Mirowska-Guzel, D., Czlonkowski, A. ve Czlonkowska, A. (2005). A prospective study of the financial costs of multiple sclerosis at different stages of the disease. European Journal of Neurology, 12(1), 31–39. https://doi.org/10.1111/j.1468-1331.2004.00950.x
Palmer, A. J., Colman, S., O’Leary, B., Taylor, B. V. ve Simmons, R. D. (2013). The Economic Impact of Multiple Sclerosis in Australia in 2010. Multiple Sclerosis Journal, 19(12), 1640–1646. https://doi.org/10.1177/1352458513488230
Péntek, M., Kobelt, G., Berg, J., Capsa, D., Dalén, J., Bíró, Z., Mátyás, K. ve Komoly, S. (2017). New Insights into the Burden and Costs of Multiple Sclerosis in Europe: Results for Hungary. Multiple Sclerosis Journal, 23(2_suppl), 91–103. https://doi.org/10.1177/1352458517708142
Place, J. (2007). Multipl Skleroz ve Diğer İnflamatuar MSS Bozuklukları. C. Warlow (Ed.), The Lancet Nörolojide Tedavi El Kitabı içinde (1. Baskı, ss. 201–222). Elsevier (Sigma Publishing).
Ropper, A. H. ve Brown, R. H. (2006). Nörolojik Hastalıkların Ana Kategorileri: Multipl Skleroz ve İlişkili Demiyelinizan Hastalıklar. M. Emre (Ed.), Adam’s and Victor’s Principles of Neurology içinde (8. Baskı, ss. 771–796). McGraw Hill-Güneş Kitabevi.
Sánchez-de la Rosa, R., Sabater, E., Casado, M. A. ve Arroyo, R. (2012). Cost-Effectiveness Analysis of Disease Modifiying Drugs (Interferons and Glatiramer Acetate) as First Line Treatments in Remitting-Relapsing Multiple Sclerosis Patients. Journal of Medical Economics, 15(3), 424–433. https://doi.org/10.3111/13696998.2012.654868
Şentürk, A. (2019). Türkiye’de MS Maliyetleri ve İlaç Pazarı Analizi. WORKSHOP Dergi, 63, 126–128.
Şentürk, A., Altıntaş, A., Sağduyu-Kocaman, A., İrkeç, C., Yandım-Kuşçu, D., Ağan-Yıldırım, K., Eraksoy, M., Kürtüncü, M., Terzi, M., Türkoğlu, R., Yanık, L., Koç, E., Erdoğan-Çiftçi, E., Becit, G., Dönmez, S., Şafak, K., Gökalp, T., & Erdoğan, A. (2018). Multiple Sclerosis Burden of Illness Study for Turkey. Value in Health Journal, 2018(21), S335–S336. https://doi.org/10.1016/j.jval.2018.09.2006
Siva, A. (2009). Merkezi Sinir Sisteminin Demiyelinizan Hastalıkları. H. Apaydın (Ed.), Nöroloji Ders Kitabı içinde (1. Baskı, ss. 747–767). İstanbul Üniversitesi Yayınları.
Soini, E., Joutseno, J. ve Sumelahti, M. L. (2017). Cost-Utility of First-Line Disease-Modifying Treatments for Relapsing–Remitting Multiple Sclerosis. Clinical Therapeutics, 39(3), 537-557.e10. https://doi.org/10.1016/j.clinthera.2017.01.028
Stenager, E. (2019). A global perspective on the burden of multiple sclerosis. The Lancet Neurology, 18(3), 227–228. https://doi.org/10.1016/S1474-4422(18)30498-8
Svendsen, B., Grytten, N., Bø, L., Aarseth, J. H., Smedal, T. ve Myhr, K. M. (2018). The economic impact of multiple sclerosis to the patients and their families in Norway. European Journal of Health Economics, 19(9), 1243–1257. https://doi.org/10.1007/s10198-018-0971-5
Taylor, B., McDonald, E., Fantino, B., Sedal, L., MacDonnell, R., Pittas, F. ve Groom, T. (2007). The Cost of Multiple Sclerosis in Australia. Journal of Clinical Neuroscience, 14(6), 532–539. https://doi.org/10.1016/j.jocn.2006.08.007
The Multiple Sclerosis Society of Ireland. (2015). Societal Cost of Multiple Sclerosis in Ireland 2015. Ireland.
Tinelli, M., Kanavos, P., Efthymiadou, O., Visintin, E., Grimaccia, F. ve Mossman, J. (2018). Using IMPrESS to Guide Policy Change in Multiple Sclerosis. Multiple Sclerosis Journal, 24(9), 1251–1255. https://doi.org/10.1177/1352458517737388
Trisolini, M., Honeycutt, A., Wiener, J. ve Lesesne, S. (2010). Global Economic Impact of Multiple Sclerosis Literature Review Executive Summary.London.
Wallin, M. T., Culpepper, W. J., Nichols, E., Bhutta, Z. A., Gebrehiwot, T. T., Hay, S. I., Khalil, I. A., Krohn, K. J., Liang, X., Naghavi, M., Mokdad, A. H., Nixon, M. R., Reiner, R. C., Sartorius, B., Smith, M., Topor-Madry, R., Werdecker, A., Vos, T., Feigin, V. L. ve Murray, C. J. L. (2019). Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18(3), 269–285. https://doi.org/10.1016/S1474-4422(18)30443-5
Walton, C., King, R., Rechtman, L., Kaye, W., Leray, E., Marrie, R. A., Robertson, N., La Rocca, N., Uitdehaag, B., van der Mei, I., Wallin, M., Helme, A., Angood Napier, C., Rijke, N. ve Baneke, P. (2020). Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis Journal, 26(14), 1816–1821. https://doi.org/10.1177/1352458520970841
Whetten-Goldstein, K., Sloan, F. A., Goldstein, L. B. ve Kulas, E. D. (1998). A Comprehensive Assessment of the Cost of Multiple Sclerosis in the United States. Multiple Sclerosis Journal, 4(5), 419–425. https://doi.org/10.1177/135245859800400504

Details

Primary Language

Turkish

Subjects

Economics

Journal Section

Review

Authors

Selin Kalender ^*
0000-0002-4377-9339
Türkiye

Publication Date

August 10, 2022

Submission Date

March 31, 2022

Acceptance Date

May 5, 2022

Published in Issue

Year 2022 Volume: 4 Number: 1

IZ

https://izlik.org/JA65ER84FS

Cite

RIS / Bibtex

APA

Kalender, S. (2022). MULTİPL SKLEROZUN EKONOMİK YÜKÜ. SDÜ Sağlık Yönetimi Dergisi, 4(1), 43-56. https://izlik.org/JA65ER84FS

AMA

1.Kalender S. MULTİPL SKLEROZUN EKONOMİK YÜKÜ. SDÜ Sağlık Yönetimi Dergisi. 2022;4(1):43-56. https://izlik.org/JA65ER84FS

Chicago

Kalender, Selin. 2022. “MULTİPL SKLEROZUN EKONOMİK YÜKÜ”. SDÜ Sağlık Yönetimi Dergisi 4 (1): 43-56. https://izlik.org/JA65ER84FS.

EndNote

Kalender S (August 1, 2022) MULTİPL SKLEROZUN EKONOMİK YÜKÜ. SDÜ Sağlık Yönetimi Dergisi 4 1 43–56.

IEEE

[1]S. Kalender, “MULTİPL SKLEROZUN EKONOMİK YÜKÜ”, SDÜ Sağlık Yönetimi Dergisi, vol. 4, no. 1, pp. 43–56, Aug. 2022, [Online]. Available: https://izlik.org/JA65ER84FS

ISNAD

Kalender, Selin. “MULTİPL SKLEROZUN EKONOMİK YÜKÜ”. SDÜ Sağlık Yönetimi Dergisi 4/1 (August 1, 2022): 43-56. https://izlik.org/JA65ER84FS.

JAMA

1.Kalender S. MULTİPL SKLEROZUN EKONOMİK YÜKÜ. SDÜ Sağlık Yönetimi Dergisi. 2022;4:43–56.

MLA

Kalender, Selin. “MULTİPL SKLEROZUN EKONOMİK YÜKÜ”. SDÜ Sağlık Yönetimi Dergisi, vol. 4, no. 1, Aug. 2022, pp. 43-56, https://izlik.org/JA65ER84FS.

Vancouver

1.Selin Kalender. MULTİPL SKLEROZUN EKONOMİK YÜKÜ. SDÜ Sağlık Yönetimi Dergisi [Internet]. 2022 Aug. 1;4(1):43-56. Available from: https://izlik.org/JA65ER84FS